Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD19 CAR-T in Relapsed/Refractory Autoimmune Diseases
NCT06680388Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and 2 more (5 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Nov 2024; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)Sjogren's syndrome
Beyond the preview
Go deeper on NCT06680388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680388.